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Introduction
The complex and heterogeneous pathophysiology of neurodegenerative diseases represents a major challenge for the discovery and development of disease modifying therapeutics. A growing body of literature implicates cellular stress-related mitochondrial and endoplasmic reticulum (ER) dysfunction and related synaptic abnormalities as a common denominator across neurodegenerative diseases, making the mitochondrial/ER/synapse axis an attractive system to target in the search for biomarkers that can be used to monitor disease progression (1) (2) (3) . Mitochondrial ATP production is critical for the bulk of neuronal processes, including neurotransmitter synthesis and synaptic plasticity. The mitochondrial complex 1 (MC1) is a critical component of ATP production, as it is where the first step of oxidative phosphorylation takes place (4) . MC1 is responsible for cellular house-keeping mechanisms such as maintaining calcium (Ca +2 ) homeostasis, producing reactive oxygen and nitrogen species (ROS and NOS) and regulating apoptosis (4) . Altered MC1 function has been associated with cell toxicity, accelerated aging and the pathogenesis of multiple neurodegenerative diseases (1) . In vivo quantification of MC1 in the brain has been made possible with the development of PET radioligand [ 18 F]BCPP-EF (5) . Characterisation of [ 18 F]BCPP-EF kinetics in the non-human primate (NHP) brain has suggested its suitability for human evaluation, but no human data has been published to date (6, 7) .
A second regulator of cellular energy is the sigma 1 receptor (s1R) which is a chaperone protein that stabilises the inositol phosphate 3 receptor (IP3R)/voltage dependent anion channel (VDAC) in the mitochondria-associated ER membrane (MAM) between the mitochondria and ER (8) . This IP3R-VDAC channel is the principal pathway for Ca +2 influx from the ER stores to the mitochondrion, with ATP production rate depending significantly on Ca +2 concentration (9) . σ1R is involved in protein sorting and folding, synaptic plasticity and neuro-protection, with human post-mortem evidence of altered expression in Alzheimer's disease (AD) (10) (11) (12) . Early PET imaging studies have used the radioligand [ 11 C]SA-4503 to evaluate s1R status in healthy, Parkinson's disease (PD) and AD cohorts, though an evaluation of the optimal imaging methodology for [ 11 C]SA-4503 has yet to be established(13-15).
The synaptic vesicle protein A (SV2A) is a membrane glycoprotein expressed ubiquitously on synaptic vesicles in presynaptic terminals and regulates Ca +2 mediated neurotransmitter release(16). SV2A has been shown to have a stable synaptic stoichiometry with good correlation to recognised synaptic density markers such as synaptophysin, and thus offers great promise as a marker of synaptic terminal density scanner. A low-dose Computed Tomography (CT) scan (30 mAs, 130 KeV, 0.55 pitch) was performed immediately before each PET scan in order to estimate attenuation. An intravenous cannula was inserted into a cubital or forearm vein for radioligand administration, and a second cannula was inserted into the radial artery to enable arterial blood collection. The radioligands were administered as a bolus (over 20 seconds) in a volume of 20 mL at the start of the PET scan. Dynamic emission data were acquired over 90 minutes following radiotracer administration and were reconstructed into 26 frames (frame durations: 8x15 s, 3 x 60 s, 5 x 120 s, 5 x 300 s, 5 x 600 s) using Discrete Inverse Fourier Transform reconstruction. Corrections were applied for attenuation, randoms and scatter.
Arterial Blood Acquisition
Whole blood activity was measured using a continuous automatic blood sampling system (Allogg AB, Marlefred, Sweden) acquired at a rate of 5 mL/min. Discrete blood samples were taken at 10, 15, 20, 25, 30, 40, 50, 60, 70, 80 and 90 minutes after scan start and total radioactivity concentration was evaluated in both blood and plasma in a Perkin Elmer 1470 10-well gamma counter. Discrete blood samples were used to determine the fraction of plasma radioactivity constituted by unchanged parent radioligand (ppf) using high-performance liquid chromatography (HPLC) analysis. For each ligand, the plasma free fraction (fp) was measured by ultrafiltration in triplicate using an arterial blood sample taken prior to tracer injection. Individual measurements of fp are given in Supplemental Table 2 .
MR Acquisition
Each subject had a T1-weighted MRI scan for coregistration with PET images. Scans were acquired on a Siemens 3T Trio clinical MRI scanner (Siemens Healthineers, Erlangen, Germany) with a 32-channel phased-array head coil using a 3D MPRAGE sequence (TE = 2.98 ms, TR = 2300 ms, cflip angle of 9 o , voxel size = 1.0 mm x1.0 mm x1.0 mm).
Image Analysis and Processing
All image data were analysed using Invicro London's in-house PET data quantification tool, MIAKAT TM (version 4.3.7, http://www.miakat.org), that implements MATLAB (version R2016a; Mathworks Inc., Natick, MA, USA), FSL (version 5.0.4; FMRIB, Oxford, UK) functions for brain extraction and SPM12 (Wellcome Trust Centre for Neuroimaging, http://www.fil.ion.ucl.ac.uk/spm) for image segmentation and registration (26) .
Each subject's MRI underwent brain extraction, grey matter (GM) segmentation and rigid body coregistration to a standard reference space (27) . The template brain image and associated CIC atlas was then nonlinearly warped to the individual subject's MRI image where the following regions of interest (ROIs) were defined: brainstem (BST), substantia nigra (SN), thalamus (TH), ventral striatum (VST), caudate (CAU), putamen (PUT), hippocampus (HIP), insular cortex (INS), temporal lobe (TL), parietal lobe (PL), frontal cortex (FTCX) and the cerebellum (CER) (28) . A centrum semiovale (CS) ROI was also generated from the automated anatomic labelling (AAL) template as defined previously for investigation as a reference region (21, 29) . PET images were registered to each subject's MRI image and corrected for motion using frame-to-frame rigid-body registration. Regional time activity curves (TACs) were generated for each ROI.
Arterial Input Function Modelling
Discrete blood samples acquired during the PET scan were fitted with a linear, constant and exponential model to determine the ppf. Optimal ppf models were identified for each tracer and applied to the total plasma activity curve to derive a metabolite corrected arterial input function.
Tracer Kinetic Modelling
All TACs were fitted with a one-tissue compartment (1TC) model, a two tissue compartment (2TC) model and graphical model multilinear analysis 1 (MA1) to estimate the volume of distribution (VT) (30) .
MA1 was applied to TAC data acquired between 30-90 minutes (t*=30 minutes) for all tracers based on an initial assessment of an appropriate temporal window. VT/fp was also assessed as an outcome measure to explore its utility in studies where there are differences in fp values.
CS has recently been explored as a reference region for [ 11 C]UCB-J (21) . Given the low white matter (WM) uptake we observed for [ 18 F]BCPP-EF, [ 11 C]SA-4503 and [ 11 C]UCB-J, we conducted a preliminary assessment of the CS as a pseudo-reference region for each ligand, and used it to calculate the distribution volume ratio (DVR). Data are presented as mean (standard deviation).
Model Comparison and Selection
The performance of 1TC and 2TC models was assessed by Akaike Information Criteria (AIC) and parameter identifiability based on the percentage standard error (SE%) derived from the covariance matrix (31) . Linear regression correlation coefficients (r 2 ) were used to compare performance between the graphical method MA1 and the compartmental models. VTs that were poorly estimated (SE%>10) were excluded from model comparisons.
Time Stability Analysis
The stability of each radiotracer over time was evaluated by exploring the performance of the tracer kinetic analysis methods for varying scan lengths. The estimated VT values were expressed as percentages of the VT estimated from the full 90 min scan (VT 90min ). These analyses were aggregated together over all subjects enabling assessment of time stability of the radiotracers in the population.
Assessment of Age Effects on outcome measures
A preliminary assessment of the effects of healthy aging on MC1, s1R and SV2A density was conducted using correlation analysis with age as the predictor variable and the PET outcome measures and ROI volume as parameters of interest. ROI volume was normalised to whole brain volumes,
where %&' is the GM volume in a given ROI and 
Results
All twelve participants completed three 90 minute dynamic PET scans including arterial blood sampling and an MRI. A summary of demographic information and individual scan parameters for each radioligand are included in Supplemental Table 3 .
Arterial Input Function Modelling
Ppf data for [ 18 F]BCPP-EF was best described by a sigmoid model with 20 (8) Figure 1 .
Tracer Kinetic Modelling
All three tracers entered the brain readily, and demonstrated a heterogenous distribution ( Figure 2 ).
[ 18 F]BCPP-EF uptake was fast and peak uptake values (SUV) ranged from 2.7 in the CS to 6.4 in the PUT at ~5-12 minutes post injection. All kinetic models tested reached convergence in the regional [ 18 F]BCPP-EF-derived TAC data ( Figure   3A ). VT was robustly estimated in all ROIs explored using both 1TC and 2TC; with AIC analysis favouring the 2TC over 1TC in all cases tested. As 2TC and MA1 derived VT were in excellent agreement (r 2 = 0.99) ( Figure 4A ), both were chosen as suitable modelling methods for [ 18 F]BCPP-EF.
VT values ranged from 11.9(2.0) ml/cm 3 in the CS to 34.0(6.6) ml/cm 3 in the PUT.
For VT estimates derived using all kinetic models are summarised for each radioligand in Table 1 . Intersubject variability of VT estimates is depicted in Figure 5 . 
Time Stability Analysis
The average time stability profile for each radiotracer is presented in Figure 6 . 
Assessment of DVR and VT/fp as outcome measures
DVR results were less variable between subjects compared to the corresponding VT estimates except for [ 11 C]SA-4503, where DVR results were more susceptible to individual differences than were the VT estimates (Supplemental Table 4 ). Correction of VT by fp had no significant effect on inter-subject variability for any of the ligands (Supplemental Table 5 ).
Assessment of age effects on outcome measures
The results of the linear regression analyses performed to investigate the relationship between age and yearly rate of change in ROI volume and VT estimates are summarised in Table 2 and Figure 7 . We observed a statically significant yearly reduction of 0.52% (r 2 = 0.50), 0.36%(r 2 = 0.59) and 0.53%( r 2 = 0.56) in TL, PL and FTCX volume, respectively ( Figure 7A ).
[ 18 F]BCPP-EF VT decreased with age most GM regions with the highest reduction of 1.68%/year (r 2 = 0.42) in the CAU ( Figure 7B) . A similar negative trend was observed for [ 11 C]SA-4503, however none of the correlations reached significance ( Figure 7C ). [ 11 C]UCB-J VT were negatively correlated with age 1 0.05, p=0.47) and [ 11 C]SA-4503 (r 2 =0.08, p=0.37) (Supplemental Figure 7) . We therefore corrected for [ 11 C]UCB-J VT by subject fp and took VT/fp as the primary outcome measure. Future [ 11 C]UCB-J studies should evaluate fp and correct for any potential inter-subject or group differences, especially when studying patient groups.
Ideally, the distribution volume of nondisplaceable ligand relative to the total concentration of ligand in plasma (VND) can be directly estimated from a reference region, which is not feasible for compounds lacking a region devoid of specific binding. DVR provides a partial solution to this problem by relying on a region with low specific binding, and in theory could be used to eliminate some of the variability associated with the estimation of individual input functions. (34) .
Conclusion
We have established a set of optimal tracer kinetic quantification models and outcome measures for 
